|
Public Act 096-1285 |
HB6459 Enrolled | LRB096 21101 RLC 36952 b |
|
|
AN ACT concerning criminal law.
|
Be it enacted by the People of the State of Illinois, |
represented in the General Assembly:
|
Section 5. The Illinois Controlled Substances Act is |
amended by changing Section 204 as follows: |
(720 ILCS 570/204) (from Ch. 56 1/2, par. 1204) |
Sec. 204. (a) The controlled substances listed in this |
Section are
included in Schedule I. |
(b) Unless specifically excepted or unless listed in |
another
schedule, any of the following opiates, including their |
isomers,
esters, ethers, salts, and salts of isomers, esters, |
and ethers,
whenever the existence of such isomers, esters, |
ethers and salts is
possible within the specific chemical |
designation: |
(1) Acetylmethadol; |
(1.1) Acetyl-alpha-methylfentanyl |
(N-[1-(1-methyl-2-phenethyl)-
|
4-piperidinyl]-N-phenylacetamide); |
(2) Allylprodine; |
(3) Alphacetylmethadol, except
|
levo-alphacetylmethadol (also known as levo-alpha-
|
acetylmethadol, levomethadyl acetate, or LAAM); |
(4) Alphameprodine; |
|
(5) Alphamethadol; |
(6) Alpha-methylfentanyl
|
(N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
|
propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
|
propanilido) piperidine; |
(6.1) Alpha-methylthiofentanyl
|
(N-[1-methyl-2-(2-thienyl)ethyl-
|
4-piperidinyl]-N-phenylpropanamide); |
(7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP); |
(7.1) PEPAP
|
(1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine); |
(8) Benzethidine; |
(9) Betacetylmethadol; |
(9.1) Beta-hydroxyfentanyl
|
(N-[1-(2-hydroxy-2-phenethyl)-
|
4-piperidinyl]-N-phenylpropanamide); |
(10) Betameprodine; |
(11) Betamethadol; |
(12) Betaprodine; |
(13) Clonitazene; |
(14) Dextromoramide; |
(15) Diampromide; |
(16) Diethylthiambutene; |
(17) Difenoxin; |
(18) Dimenoxadol; |
(19) Dimepheptanol; |
|
(20) Dimethylthiambutene; |
(21) Dioxaphetylbutyrate; |
(22) Dipipanone; |
(23) Ethylmethylthiambutene; |
(24) Etonitazene; |
(25) Etoxeridine; |
(26) Furethidine; |
(27) Hydroxpethidine; |
(28) Ketobemidone; |
(29) Levomoramide; |
(30) Levophenacylmorphan; |
(31) 3-Methylfentanyl
|
(N-[3-methyl-1-(2-phenylethyl)-
|
4-piperidyl]-N-phenylpropanamide); |
(31.1) 3-Methylthiofentanyl
|
(N-[(3-methyl-1-(2-thienyl)ethyl-
|
4-piperidinyl]-N-phenylpropanamide); |
(32) Morpheridine; |
(33) Noracymethadol; |
(34) Norlevorphanol; |
(35) Normethadone; |
(36) Norpipanone; |
(36.1) Para-fluorofentanyl
|
(N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
|
4-piperidinyl]propanamide); |
(37) Phenadoxone; |
|
(38) Phenampromide; |
(39) Phenomorphan; |
(40) Phenoperidine; |
(41) Piritramide; |
(42) Proheptazine; |
(43) Properidine; |
(44) Propiram; |
(45) Racemoramide; |
(45.1) Thiofentanyl
|
(N-phenyl-N-[1-(2-thienyl)ethyl-
|
4-piperidinyl]-propanamide); |
(46) Tilidine; |
(47) Trimeperidine; |
(48) Beta-hydroxy-3-methylfentanyl (other name:
|
N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
|
N-phenylpropanamide). |
(c) Unless specifically excepted or unless listed in |
another
schedule, any of the following opium derivatives, its |
salts, isomers
and salts of isomers, whenever the existence of |
such salts, isomers and
salts of isomers is possible within the |
specific chemical designation: |
(1) Acetorphine; |
(2) Acetyldihydrocodeine; |
(3) Benzylmorphine; |
(4) Codeine methylbromide; |
(5) Codeine-N-Oxide; |
|
(6) Cyprenorphine; |
(7) Desomorphine; |
(8) Diacetyldihydromorphine (Dihydroheroin); |
(9) Dihydromorphine; |
(10) Drotebanol; |
(11) Etorphine (except hydrochloride salt); |
(12) Heroin; |
(13) Hydromorphinol; |
(14) Methyldesorphine; |
(15) Methyldihydromorphine; |
(16) Morphine methylbromide; |
(17) Morphine methylsulfonate; |
(18) Morphine-N-Oxide; |
(19) Myrophine; |
(20) Nicocodeine; |
(21) Nicomorphine; |
(22) Normorphine; |
(23) Pholcodine; |
(24) Thebacon. |
(d) Unless specifically excepted or unless listed in |
another
schedule, any material, compound, mixture, or |
preparation which contains
any quantity of the following |
hallucinogenic substances, or which
contains any of its salts, |
isomers and salts of isomers, whenever the
existence of such |
salts, isomers, and salts of isomers is possible
within the |
specific chemical designation (for the purposes of this
|
|
paragraph only, the term "isomer" includes the optical, |
position and
geometric isomers): |
(1) 3,4-methylenedioxyamphetamine
|
(alpha-methyl,3,4-methylenedioxyphenethylamine,
|
methylenedioxyamphetamine, MDA); |
(1.1) Alpha-ethyltryptamine
|
(some trade or other names: etryptamine;
|
MONASE; alpha-ethyl-1H-indole-3-ethanamine;
|
3-(2-aminobutyl)indole; a-ET; and AET); |
(2) 3,4-methylenedioxymethamphetamine (MDMA); |
(2.1) 3,4-methylenedioxy-N-ethylamphetamine
|
(also known as: N-ethyl-alpha-methyl-
|
3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
|
and MDEA); |
(2.2) N-Benzylpiperazine (BZP); |
(3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA); |
(4) 3,4,5-trimethoxyamphetamine (TMA); |
(5) (Blank); |
(6) Diethyltryptamine (DET); |
(7) Dimethyltryptamine (DMT); |
(8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP); |
(9) Ibogaine (some trade and other names:
|
7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
|
6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
|
indole; Tabernanthe iboga); |
(10) Lysergic acid diethylamide; |
|
(10.5) Salvia divinorum (meaning all parts of the plant |
presently classified
botanically as Salvia divinorum, |
whether growing or not, the
seeds thereof, any extract from |
any part of that plant, and every compound,
manufacture, |
salts, isomers, and salts of
isomers whenever the existence |
of such salts, isomers, and salts of
isomers is possible |
within the specific chemical designation, derivative, |
mixture, or preparation of that plant, its
seeds or |
extracts);
|
(11) 3,4,5-trimethoxyphenethylamine (Mescaline); |
(12) Peyote (meaning all parts of the plant presently |
classified
botanically as Lophophora williamsii
Lemaire, |
whether growing or not, the
seeds thereof, any extract from |
any part of that plant, and every compound,
manufacture, |
salts, derivative, mixture, or preparation of that plant, |
its
seeds or extracts); |
(13) N-ethyl-3-piperidyl benzilate (JB 318); |
(14) N-methyl-3-piperidyl benzilate; |
(14.1) N-hydroxy-3,4-methylenedioxyamphetamine
|
(also known as N-hydroxy-alpha-methyl-
|
3,4(methylenedioxy)phenethylamine and N-hydroxy MDA); |
(15) Parahexyl; some trade or other names:
|
3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
|
dibenzo (b,d) pyran; Synhexyl; |
(16) Psilocybin; |
(17) Psilocyn; |
|
(18) Alpha-methyltryptamine (AMT); |
(19) 2,5-dimethoxyamphetamine
|
(2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA); |
(20) 4-bromo-2,5-dimethoxyamphetamine
|
(4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
|
4-bromo-2,5-DMA); |
(20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
|
Some trade or other names: 2-(4-bromo-
|
2,5-dimethoxyphenyl)-1-aminoethane;
|
alpha-desmethyl DOB, 2CB, Nexus; |
(21) 4-methoxyamphetamine
|
(4-methoxy-alpha-methylphenethylamine;
|
paramethoxyamphetamine; PMA); |
(22) (Blank); |
(23) Ethylamine analog of phencyclidine.
|
Some trade or other names:
|
N-ethyl-1-phenylcyclohexylamine,
|
(1-phenylcyclohexyl) ethylamine,
|
N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE; |
(24) Pyrrolidine analog of phencyclidine. Some trade |
or other names:
1-(1-phenylcyclohexyl) pyrrolidine, PCPy, |
PHP; |
(25) 5-methoxy-3,4-methylenedioxy-amphetamine; |
(26) 2,5-dimethoxy-4-ethylamphetamine
|
(another name: DOET); |
(27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
|
|
(another name: TCPy); |
(28) (Blank); |
(29) Thiophene analog of phencyclidine (some trade
|
or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
|
2-thienyl analog of phencyclidine; TPCP; TCP); |
(30) Bufotenine (some trade or other names:
|
3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
|
3-(2-dimethylaminoethyl)-5-indolol;
|
5-hydroxy-N,N-dimethyltryptamine;
|
N,N-dimethylserotonin; mappine) ; . |
(31) 1-Pentyl-3-(1-naphthoyl)indole |
Some trade or other names: JWH-018; |
(32) 1-Butyl-3-(1-naphthoyl)indole |
Some trade or other names: JWH-073. |
(e) Unless specifically excepted or unless listed in |
another
schedule, any material, compound, mixture, or |
preparation which contains
any quantity of the following |
substances having a depressant effect on
the central nervous |
system, including its salts, isomers, and salts of
isomers |
whenever the existence of such salts, isomers, and salts of
|
isomers is possible within the specific chemical designation: |
(1) mecloqualone; |
(2) methaqualone; and |
(3) gamma hydroxybutyric acid. |
(f) Unless specifically excepted or unless listed in |
another schedule,
any material, compound, mixture, or |
|
preparation which contains any quantity
of the following |
substances having a stimulant effect on the central nervous
|
system, including its salts, isomers, and salts of isomers: |
(1) Fenethylline; |
(2) N-ethylamphetamine; |
(3) Aminorex (some other names:
|
2-amino-5-phenyl-2-oxazoline; aminoxaphen;
|
4-5-dihydro-5-phenyl-2-oxazolamine) and its
|
salts, optical isomers, and salts of optical isomers; |
(4) Methcathinone (some other names:
|
2-methylamino-1-phenylpropan-1-one;
|
Ephedrone; 2-(methylamino)-propiophenone;
|
alpha-(methylamino)propiophenone; N-methylcathinone;
|
methycathinone; Monomethylpropion; UR 1431) and its
|
salts, optical isomers, and salts of optical isomers; |
(5) Cathinone (some trade or other names:
|
2-aminopropiophenone; alpha-aminopropiophenone;
|
2-amino-1-phenyl-propanone; norephedrone); |
(6) N,N-dimethylamphetamine (also known as:
|
N,N-alpha-trimethyl-benzeneethanamine;
|
N,N-alpha-trimethylphenethylamine); |
(7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
|
4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine). |
(g) Temporary listing of substances subject to emergency |
scheduling.
Any material, compound, mixture, or preparation |
that contains any quantity
of the following substances: |
|
(1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
|
(benzylfentanyl), its optical isomers, isomers, salts,
|
and salts of isomers; |
(2) N-[1(2-thienyl)
|
methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl),
|
its optical isomers, salts, and salts of isomers. |
(Source: P.A. 95-239, eff. 1-1-08; 95-331, eff. 8-21-07; |
96-347, eff. 1-1-10.)
|